Latest News

Why Ocugen Stock Is Rallying While Moderna, Novavax, Vaxart Can’t Catch Up

0

Morningstar Research

Analyst Report: Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead’s acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead’s exposure to cell therapy and noncell therapy in oncology.

AT&T’s Charts Are Putting Off Bad Signals

Previous article

Cathie Wood’s ARK Funds Snapped Up Crispr Shares Ahead of Plunge

Next article

You may also like

Comments

Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News